Listen: Vaccine riches, patent waivers, & a gene therapy for aging
What does $45 billion buy you these days? Is clinical trial tourism a business? And will no one think of the patents? We cover all that and more this week …
Read MoreTag: The Readout LOUD
Virologist Angela Rasmussen on the controversy surrounding Russia’s Sputnik V Covid-19 vaccine
By all accounts, the Covid-19 vaccine developed by Russia’s Gamaleya Institute, called Sputnik V, has looked really good. In a study published in The Lancet in February, the vaccine’s efficacy …
Read More
Listen: Biden’s punt on drug prices, Russia’s vaccine controversy, & the importance of tiny plastic cones
Does President Biden really care about drug prices? Is Sputnik V falling out of orbit? And why’s it so hard to find pipette tips? We cover all that and more …
Read More
Listen: The latest mask debate, FDA in limbo, & gene therapy’s uncertain upside
When can we stop wearing masks outside? Are we ever getting a permanent FDA commissioner? And is curing disease a good business? We cover all that and more this week …
Read More
‘We did need to throw a lot of spaghetti against the Covid window’: a biotech analyst on pandemic drug development
The pandemic has shined a spotlight on the biopharmaceutical industry, proving its value through the speed of vaccine development to a society that ranked it even lower in its esteem …
Read More
Listen: J&J’s vaccine pause, how to talk about remote risks, & why we don’t have new drugs for Covid-19
How do you describe a one-in-a-million risk? What’s heparin-induced thrombocytopenia? And why’s it so hard to find drugs for Covid-19? We cover all that and more this week on “The …
Read More
AstraZeneca’s latest vaccine woes, the compassionate use dilemma, & what it’s like to give out Covid vaccines
What’s next for AstraZeneca? Are there any right answers when it comes to compassionate use? And how does it feel to give someone a Covid-19 vaccine? We cover all that …
Read More
What to make of the AstraZeneca vaccine data — and the surrounding controversy
AstraZeneca’s up-and-down quest to develop a vaccine for Covid-19 stands out from what has otherwise been a remarkably straightforward process in the U.S. And the latest twist for AstraZeneca’s vaccine, …
Read More
AstraZeneca and the very good, then quite bad, then deeply confusing week
Who’s to blame for the AstraZeneca vaccine scandal? Can boldness backfire for pharma CEOs? And is the U.S.-U.K. special relationship on the rocks? We discuss all that and more this …
Read More